<DOC>
	<DOC>NCT00809289</DOC>
	<brief_summary>This Phase 1 study will assess the effects of esreboxetine on the heart. In particular the effects on a specific electrocardiogram (ECG) measurement called QTc will be measured.</brief_summary>
	<brief_title>Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy male and female subjects aged 18 to 55 years Body mass Index of approximately 18 to 30kg/m2 Informed consent document signed by the subject or a legally acceptable representative Subjects who are willing and able to comply with the scheduled visits, treatment tests, laboratory tests, and other study procedures Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic psychiatric, neurologic or allergic disease or clinical findings at screening Conditions possibly affecting drug absorption 12lead ECg demonstrating QTc &gt; 450ms or any other clinically significant abnormalities at screen Positive urine drug screen Hypersensitivity to moxifloxacin Unwilling or unable to comply with the lifestyle guidelines in the protocol Treatment with an investigational drug within 3 months or 5 half lives (whichever is longer) preceding the first dose of study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Thorough QT/QTc study</keyword>
</DOC>